Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Starts Arrowhead Pharma (ARWR) at Buy
- DHT Holdings Q2 TCE earnings estimated at $126,700 per day
- Empire State Building launches family bundle with up to 20% off tickets
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
